{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+disoproxil%2Femtricitabine&page=11", "query": { "intervention": "tenofovir disoproxil/emtricitabine", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 339, "total_pages": 34, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+disoproxil%2Femtricitabine&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tenofovir+disoproxil%2Femtricitabine&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:04:26.743Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02962739", "title": "The Cellular Pharmacology of F-TAF in Dried Blood Spots", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "emtricitabine 200 mg/tenofovir alafenamide 25mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 38, "start_date": "2016-03", "completion_date": "2019-05-22", "has_results": true, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02962739" }, { "nct_id": "NCT00244712", "title": "Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "emtricitabine/tenofovir", "type": "DRUG" }, { "name": "abacavir/lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 688, "start_date": "2005-07", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2010-06-08", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 72, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244712" }, { "nct_id": "NCT05378399", "title": "SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "Substance Use", "Adherence, Medication", "Adherence, Treatment" ], "interventions": [ { "name": "Descovy or Truvada", "type": "DRUG" }, { "name": "ID-Cap System", "type": "DEVICE" }, { "name": "Beiwe", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2022-12-20", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05378399" }, { "nct_id": "NCT04493216", "title": "A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "FTC/TAF", "type": "DRUG" }, { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2020-11-18", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 9, "location_summary": "Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493216" }, { "nct_id": "NCT03472963", "title": "Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Single dose of Genvoya® and a single 800 mg dose of Darunavir®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "MALE", "summary": "18 Years to 49 Years · Male only" }, "enrollment_count": 35, "start_date": "2018-04-27", "completion_date": "2019-03-29", "has_results": false, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472963" }, { "nct_id": "NCT02431247", "title": "A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immunodeficiency Virus Type 1, Human" ], "interventions": [ { "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC", "type": "DRUG" }, { "name": "DRV/COBI FDC", "type": "DRUG" }, { "name": "FTC/TDF FDC", "type": "DRUG" }, { "name": "D/C/F/TAF FDC - Matching Placebo", "type": "DRUG" }, { "name": "FTC/TDF FDC Matching Placebo", "type": "DRUG" }, { "name": "DRV/COBI FDC Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Sciences Ireland UC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 725, "start_date": "2015-07-06", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431247" }, { "nct_id": "NCT06613685", "title": "Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "lepetegravir", "type": "DRUG" }, { "name": "lenacapavir pacfosacil", "type": "DRUG" }, { "name": "Bictegravir/emtricitabine/tenofovir alafenamide", "type": "DRUG" }, { "name": "lepetegravir/lenacapavir pacfosacil FDC", "type": "DRUG" }, { "name": "Placebo to Match BVY", "type": "DRUG" }, { "name": "Placebo to Match GS1720/GS-4182 FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2024-10-21", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Torrance, California • West Hollywood, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06613685" }, { "nct_id": "NCT00666055", "title": "Sex, Aging and Antiretroviral Pharmacokinetics", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ARV regimen chosen by treating physician", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kristine Patterson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2008-03", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-09-20", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666055" }, { "nct_id": "NCT00924898", "title": "Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute HIV Infection", "HIV Infections" ], "interventions": [ { "name": "efavirenz, emtricitabine, and tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2005-01", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924898" }, { "nct_id": "NCT00298363", "title": "Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "Tenofovir disoproxil fumarate (tenofovir DF; TDF)", "type": "DRUG" }, { "name": "Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)", "type": "DRUG" }, { "name": "Entecavir (ETV)", "type": "DRUG" }, { "name": "TDF placebo", "type": "DRUG" }, { "name": "FTC/TDF placebo", "type": "DRUG" }, { "name": "ETV placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 112, "start_date": "2006-04", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2013-04-25", "last_synced_at": "2026-10-14T02:04:26.743Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298363" } ] }